RFM.F Sensorion SAS
- Market cap
- EUR 1.95M
- P/E
- -
- P/B
- 0.98x
- ROE
- -66.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is RFM.F undervalued?
Graham numberThe Graham number of Sensorion SAS cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Sensorion SAS fundamental analysis
No fundamental analysis for Sensorion SAS yet.
Sensorion SAS stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Sensorion SAS
Sensorion SA, a biotechnology company, engages in the development of novel therapies to restore, treat, and prevent hearing loss disorders in France. The company develops SENS-501, a dual AAV vector gene therapy development product for restoring hearing in patients with mutations in OTOF gene in Phase 1/2 clinical trials; and SENS-601, a candidate for the treatment of hearing loss caused by mutations of the GJB2 gene in preclinical studies. It is also developing SENS-40, a s…
Full company profileSensorion SAS financial statements
Sensorion SAS annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 330K | 140K | 0.00 | 0.00 | 0.00 |
| Operating Income | -15.0M | -23.1M | -22.3M | -28.4M | -30.8M |
| EBITDA | - | -22.3M | -21.5M | -25.4M | -29.0M |
| Net Income | -15.1M | -23.2M | -22.1M | -26.0M | -29.4M |
| EPS | -0.19 | -15 | -5.90 | -4.32 | -4.90 |
| Balance Sheet | |||||
| Total Assets | 59.1M | 38.9M | 46.5M | 89.3M | 57.9M |
| Total Liabilities | 15.0M | 17.1M | 13.2M | 17.1M | 13.4M |
| Shareholders' Equity | 44.1M | 21.9M | 33.3M | 72.1M | 44.5M |
| Cash & Short-term Investments | 50.0M | 26.2M | 37.0M | 66.8M | 47.5M |
| Cash Flow | |||||
| Operating Cash Flow | -10.8M | -21.4M | -20.8M | -21.3M | -27.3M |
| Capital Expenditure | 653K | 1.51M | 870K | 1.12M | 756K |
| Free Cash Flow | -11.4M | -22.9M | -21.6M | -22.5M | -28.0M |
| Ratios | |||||
| ROE | -34.4% | -106.0% | -66.3% | -36.0% | -66.2% |
| ROA | -25.6% | -59.6% | -47.4% | -29.1% | -50.8% |
| Net Profit Margin | -4,587.9% | -16,572.0% | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Sensorion SAS dividends
Sensorion SAS has not paid dividends in the last 5 fiscal years.
Last stock split: 1:50 on Sep 15, 2026.
Who owns Sensorion SAS
- Insiders 34.76%
- Institutions 32.48%
- Public & others 32.76%
- Shares outstanding 10.3M
- Free float 6.01M
Sensorion SAS company profile
- Company name
- Sensorion SAS
- Ticker
- RFM.F
- ISIN
- FR0012596468
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 63
- Fiscal year end
- December
- Address
- 375, rue du Professeur Joseph Blayac, Montpellier, France, 34080
- Phone
- 33 4 67 20 77 30
- Website
- sensorion.com
About Sensorion SAS
Sensorion SA, a biotechnology company, engages in the development of novel therapies to restore, treat, and prevent hearing loss disorders in France. The company develops SENS-501, a dual AAV vector gene therapy development product for restoring hearing in patients with mutations in OTOF gene in Phase 1/2 clinical trials; and SENS-601, a candidate for the treatment of hearing loss caused by mutations of the GJB2 gene in preclinical studies. It is also developing SENS-40, a small molecule in Phase 2b clinical trials to treat sudden sensorineural hearing loss; prevention of residual hearing loss following cochlear implantation in Phase 2a clinical trials; and prevention of cisplatin-induced ototoxicity in Phase 2a clinical trials. The company was incorporated in 2009 and is headquartered in Montpellier, France.
Sensorion SAS management
7- Mr. Frederic Chereau M.B.A.Chief Executive Officer · born 1967
- Ms. Laurene DanonChief Financial Officer
- Mr. Bernd SchmidtChief Technical Officer
- Ms. Christine Le BecHead of CMC Gene Therapy
- Ms. Stephanie FilipeHead of Business Operations & Portfolio Management
- Mr. Laurent DesireHead of Preclinical Development
- Ms. Rachel CooperHead of Audiology